Stock analysts at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN - Get Free Report) in a research note issued on Friday. The firm set a "sell" rating on the biotechnology company's stock.
Separately, Lake Street Capital dropped their price objective on shares of Evogene from $30.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, August 23rd.
Read Our Latest Research Report on Evogene
Evogene Stock Up 1.3 %
Shares of NASDAQ EVGN traded up $0.03 during mid-day trading on Friday, reaching $2.43. 36,120 shares of the company were exchanged, compared to its average volume of 19,951. The company's 50-day simple moving average is $2.93 and its 200-day simple moving average is $5.14. The stock has a market capitalization of $100.15 million, a P/E ratio of -5.28 and a beta of 1.40. Evogene has a twelve month low of $2.14 and a twelve month high of $10.40.
Evogene (NASDAQ:EVGN - Get Free Report) last posted its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The company had revenue of $0.91 million for the quarter.
Institutional Trading of Evogene
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 10,000 shares of the biotechnology company's stock, valued at approximately $31,000. Institutional investors own 10.40% of the company's stock.
About Evogene
(
Get Free Report)
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Recommended Stories
Before you consider Evogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evogene wasn't on the list.
While Evogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
